Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
暂无分享,去创建一个
D. Berry | E. Shpall | G. Broadwater | W. Petros | D. Rizzieri | N. Chao | J. Vredenburgh | G. Long | M. Ross | M. Affronti | R. Jones | W. Peters | C. Gilbert | M. Elkordy | D. Coniglio | A. Hussein | P. Rubin
[1] P. Zola,et al. Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival. , 1997, Anticancer research.
[2] J. Armitage,et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Wingo,et al. Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.
[4] B A Miller,et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. , 1996, Journal of the National Cancer Institute.
[5] G. Hortobagyi,et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L. Seymour,et al. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Fairclough,et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Hortobagyi,et al. Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support , 1994, Cancer.
[9] G. Rosner,et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Marks,et al. Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.
[11] D. Cox. Regression Models and Life-Tables , 1972 .